**Chapter 9**

*Viruses and Viral Infections in Developing Countries*

geography of measles vaccination in the African Great Lakes region. Nature Communications. 2017;**8**:15585. DOI:

[39] Arlett P, Portier G, de Lisa R, Blake K, Wathion N, Dogne J-M, et al. Proactively managing the risk of marketed drugs: Experience with the EMA pharmacovigilance risk assessment committee. Nature Reviews Drug Discovery. 2014;**13**:395-397. DOI:

[40] Health Canada. Lifecycle Approach Model. Health Products and Food Regulatory Modernization. 2012. Available from: http://www.hc-sc.gc.ca/ ahc-asc/activit/strateg/mod/ini/index-

[41] Institute of Medicine. Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Washington, DC: The National Academies Press; 2012

[42] Standing Senate Committtee on Social Affairs, Science and Technology. Prescription Pharmaceuticals in Canada Post-Approval Monitoring of Safety and Effectiveness. Ottawa: Standing Senate Committtee on Social Affairs, Science

[43] Pagliusi S, Jain R, Suri RK. Vaccines, our shared responsibilities. Vaccine. 2015;**33**:2197-2202. DOI: 10.1016/j.

[44] Salama P, Assefa F, Talley L, Spiegel P, van Der Veen A, Gotway CA. Malnutrition, measles, mortality, and the humanitarian response during a famine in Ethiopia. Journal of the American Medical Association. 2001;**286**:563-571. DOI: 10.1001/

[45] Edelson PJ. Patterns of measles transmission among airplane travellers. Travel Medicine and Infectious Disease. 2012;**10**(5-6):230-235. DOI: 10.1016/j.

and Technology; 2013

vaccine.2015.02.065

jama.286.5.563

tmaid.2012.10.003

10.1038/ncomms15585

10.1038/nrd3713-c1

eng.php

[30] Holzmann H, Hengel H, Tenbusch M, Doerr H. Eradication of measles: Remaining challenges. Medical Microbiology and Immunology. 2016;**205**(3):201-208. DOI: 10.1007/

[31] White DO, Fenner FJ. Medical Virology. 4th ed. San Diego, California: Academic Press, a division of Harcourt Brace and Company; 1994. pp. 461-465

[32] Onoja AB, Adeniji AJ. Kinetics of measles antibody by haemagglutination inhibition assay in children in southwest and north-central Nigerian state. International Journal of Infectious Diseases. 2013;**17**(7):552-555. DOI:

[33] Onoja AB, Hamid KM, Adeniji JA, Mukhtar MD. Implication of vaccination on measles reduction and elimination in Nigeria. African Journal of Medicine and Medical Sciences. 2014;**43**(Suppl 1):

[34] CDC. Progress in global measles control and mortality reduction, 2000- 2007. Morbidity and Mortality Weekly Report. 2008;**57**(48):1303-1306

[35] Zarocostas J. Mortality from measles fell by 91% in Africa from 2000 to 2006. BMJ. 2007;**335**(7631):1173. DOI:

10.1136/bmj.39419.393275.DB

[36] Lessler J, Metcalf CJE, Grais RF, Luquero FJ, Cummings DAT, Grenfell BT. Measuring the performance of vaccination programs using crosssectional surveys: A likelihood

framework and retrospective analysis. PLoS Medicine. 2011;**8**(10):e1001110. DOI: 10.1371/journal.pmed.1001110

[37] WHO. Global Vaccine Action Plan 2011-2020. 2013. Available from: http://www.who.int/immunization/ global\_vaccine\_action\_plan/en/

[38] Takahashi S, Metcalf CJE, Ferrari MJ, Tatem AJ, Lessler J. The

10.1016/j.ijid.2013.02.001

73-78

s00430-016-0451-4

**126**
